Jerry Molitor, MD
Rheumatology · Minneapolis, MNNPI 1235147331
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,259 of the $12,969 with a category attached, or 79.1%. Boehringer Ingelheim accounts for 69.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $6,336 and has fallen 57.0% since, to $2,724 in 2025.
Across 25 payments — averaging $518.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$9K
- Boehringer Ingelheim International GmbH$2K
- AstraZeneca$1K
Across 13 payments — averaging $16,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$101K
- Kadmon Corporation LLC$48K
- Pfizer$38K
- Sanofi US Services Inc.$32K
What the payments were for
- Consulting fees$10,25979%
- Travel & lodging$2,07916%
- Food & beverage$6315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $9,061 |
| Boehringer Ingelheim International GmbH | 2 | $2,475 |
| AstraZeneca | 11 | $1,434 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,969 in reported general payments places this provider in the 85th percentile of 121 rheumatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 12 | $54,301 |
| Cevimeline Hcl | 45 | $12,563 |
| Mycophenolate Mofetil | 51 | $7,010 |
| Sildenafil Citrate | 25 | $5,175 |
| Hydroxychloroquine Sulfate | 94 | $3,536 |
| MethotrexateMethotrexate Sodium | 70 | $2,352 |
| Pentoxifylline | 32 | $1,253 |
| Esomeprazole Magnesium | 22 | $1,049 |
| Omeprazole | 44 | $807 |
| Pilocarpine Hcl | 22 | $771 |
| Prednisone | 57 | $749 |
| Famotidine | 34 | $482 |
| Pantoprazole Sodium | 26 | $350 |
| Amlodipine Besylate | 16 | $349 |
| Levocetirizine Dihydrochloride | 29 | $259 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Minneapolis
- Parastoo FazeliMinneapolis$149K
- Gary BryantMinneapolis$4K
- Saud AbaalkhailMinneapolis$3K
- Anna ShmagelMinneapolis$948
- Linh NgoMinneapolis$94
- Asim KhanMaple Grove$1.2M
- Robert TierneySt Louis Park$137K
- Ali SajjadMaplewood$87K
- Steven YtterbergRochester$87K
- Cornelia WeyandRochester$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.